Effect of biphasic insulin aspart 30/70 (BIAsp30) in combination with metformin on glycaemic control in subjects with type 2 diabetes not optimally controlled on oral antidiabetic agents

被引：0
|
作者：
Naiker, P.
Makan, H. A.
Omar, M. A. K.
Kedijang, T.
Kong, L. L. L.
机构：
[1] St Augustines Hosp, Durban, South Africa
[2] Novo Nordisk, Johannesburg, South Africa
[3] Novo Nordisk, Singapore, Singapore
来源：
DIABETOLOGIA | 2006年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0983
引用
收藏
页码：599 / 600
页数：2
相关论文
共 50 条
  • [31] Thrice-daily biphasic insulin aspart 30 may be another therapeutic option for Chinese patients with type 2 diabetes inadequately controlled with oral antidiabetic agents
    Yang Wen-ying
    Ji Qiu-he
    Zhu Da-long
    Yang Jin-kui
    Chen Lu-lu
    Liu Zhi-min
    Yu De-min
    Yan Li
    CHINESE MEDICAL JOURNAL, 2009, 122 (14) : 1704 - 1708
  • [32] Insulin degludec/insulin aspart (IDegAsp) twice daily (BID) vs biphasic insulin aspart 30 (BIAsp 30) BID: a randomised trial in Chinese patients with type 2 diabetes
    Ma, J.
    Yang, W.
    Hong, T.
    Liu, M.
    Miao, H.
    Peng, Y.
    Wang, C.
    Xu, X.
    Yang, T.
    Liu, W.
    Nielsen, A. Moeller
    Pan, L.
    Weigang, Z.
    DIABETOLOGIA, 2018, 61 : S410 - S411
  • [33] Efficacy and safety of BlAsp 30 (Biphasic insulin aspart 30) TID in combination with oral hypoglycaernic agents in non-obese patients with type 2 diabetes
    Lund, S. S.
    Tarnow, L.
    Nielsen, B. B.
    Parving, H.-H.
    Pedersen, O.
    Vaag, A. A.
    DIABETOLOGIA, 2007, 50 : S409 - S409
  • [34] Biphasic Insulin Aspart 30 (BIAsp 30) Improves Glycemic Control in Patients with Type 2 Diabetes Regardless of Previous Treatment Regimens: The IMPROVE Study in Iran
    Esteghamati, Alireza
    Rajabian, Reza
    Amini, Masoud
    Bahrami, Amir
    Khamseh, Mohammad Ebrahim
    Ardekani, Mohammad
    Rizi, Ehsan Parvaresh
    DIABETES, 2009, 58 : A516 - A516
  • [35] The Efficacy and Safety of Insulin Aspart 30 plus Metformin vs. Insulin Aspart 30 Alone in Treatment for Subjects with Type 2 Diabetes: A Randomized Controlled Trial
    Guo, Lixin, Sr.
    Chen, Li
    Chang, Bao Cheng
    Yang, Li Yong
    Liu, Yu
    Feng, Bo
    DIABETES, 2017, 66 : A255 - A255
  • [36] Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts)
    Raskin, P.
    Matfin, G.
    Schwartz, S. L.
    Chaykin, L.
    Chu, P. -L.
    Braceras, R.
    Wynne, A.
    DIABETES OBESITY & METABOLISM, 2009, 11 (01): : 27 - 32
  • [37] Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: A multicenter, observational, primary care study conducted in Finland
    Makela, Jyrki K.
    Schmuser, Christine
    Askonen, Kari
    Saukkonen, Tero
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2012, 95 (01) : 10 - 18
  • [38] Comparison of the cost to reach A1C targets in patients with type-2 diabetes mellitus on oral antidiabetic agents and either biphasic insulin aspart 70/30 or insulin glargine
    Cobden, D
    Allen, E
    Botteman, M
    VALUE IN HEALTH, 2005, 8 (03) : 358 - 358
  • [39] UNDERSTANDING PATIENTS' WILLINGNESS TO PAY (WTP) FOR BIPHASIC INSULIN ASPART 30/70 (BIASP30) IN A FLEXPEN® DEVICE OR USING A PENFILL® FOR TYPE 2 DIABETES (T2D) TREATMENT IN AN OUT-OF-POCKET PAYMENTS MARKET
    Murthy, S.
    Aneja, P.
    Asirvatham, A.
    Ramabhat, B.
    Husemoen, Nystrup L. L.
    Rhee, N. A.
    Kesavadev, J.
    VALUE IN HEALTH, 2019, 22 : S160 - S160
  • [40] Clinical Experience with Biphasic Insulin Aspart 30 Treatment in Patients with Type 2 Diabetes Poorly Controlled on Oral Antidiabetic Drugs: The Turkish PRESENT Study
    Guler, Serdar
    Tuna, Siebnem
    Bech, Ole
    TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2008, 12 (01) : 4 - 9
12345